IL6 and prostate carcinoma: Interestingly, one study shows that Meth-AEA induces IL-6 secretion by prostate cancer cells, and this effect is inhibited by CB2 receptor antagonist SR144528 and not by CB1 receptor antagonist rimonabant [39].